Phase 3 N=114 Irbesartan and Atenolol in Hypertensive Heart Disease
Hypertension
Primary: Changes in Left Ventricular Mass Index — -1; -9; -6; -14 g/m^2
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=100 Association Between Genetic Polymorphism of Beta-adrenergic Receptor and Effects of Bisoprolol in Korean Heart Failure Patients.
Chronic Heart Failure
Primary: Change From Baseline in Echocardiographic Left Ventricular Ejection Fraction (LVEF) According to the Genetic Polymorphism of Beta-1 Adrenergic Receptor-CG at Week 26 or…
Phase 4 N=209 An Active-controlled, Clinical Trial to Assess Central Hemodynamic Effects of Bisoprolol in Hypertensive Patients (Central Hemodynamic Assessment Measured in Patient With HypertensION [CHAMPION])
Hypertension
Primary: Change From Baseline in Aortic Pulse Pressure (APP) in Intention to Treat (ITT) Population at Week 12 — 47.49; 45.93; -4.40; -3.69 Millimeter of mercury (mmHg) — p=0.5943
Phase 3 N=17 Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
Peripheral Artery Disease · Hypertension
Primary: Peak Walking Time (PWT) — 110.4; -19.4 seconds — p=0.039
N/A N=38 Genetically Determined Response to Atenolol in Patients With Persistent Atrial Fibrillation
Atrial Fibrillation
Primary: Change in Pre- and Post-atenolol Ventricular Rate Response After 5 Minutes of Exercise — -10; -13 beats per minute
Phase 4 N=70 Pilot - Peri-operative Beta Blockade
Adrenergic Beta-Receptor Blockader · Troponin Levels · Cardiomyopathy, Post-surgical
Primary: Difference in hscTnI Values — 3.4; 2.8 ng/L
N/A N=25 Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
Hypertension · Female Sexual Dysfunction
Primary: Change in Female Sexual Function Index — 1.24; 1.42 units on a scale
N/A N=220 Beta-Blockers in Heart Failure: Pharmacy-level Intervention Comparison
Heart Failure
Primary: Rate of Adherence to Guideline Prescription — 4; 6 patients
N/A N=579 An Observational Study of Beta-Blocker Use in Patients With COPD and Acute MI
Pulmonary Disease, Chronic Obstructive
Primary: Prevalence of COPD in Patients Admitted to the Hospital With an Acute Myocardial Infarction (AMI) — 562 Participants
N/A N=154 Genetic Determinants of Response to Beta Blockade
Healthy
Primary: Reduction in Heart Rate — 7.9; 6; 3.3; 9.6 beats per minute
Phase 4 N=26 Beta Blockade in in Traumatic Brain Injury
Brain Injuries, Traumatic
Primary: Mortality — 7.7; 33.3 percentage of participants
Phase 4 N=50 BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Heart Failure With Preserved Ejection Fraction · Hypertension
Primary: Difference in Home Systolic Blood Pressure — 130.7; 134.5 mm Hg — p=0.017
Phase 3 N=12 A Study of the Effect of Nebivolol to Evaluate Its Vasodilatory Effects in Hypertensive Patients
Hypertension
Primary: Percentage Change From Baseline to End of Treatment for the Difference Between the Post-ischemia and Pre-ischemia Forearm Vascular Resistance (FVR).
Phase 2 N=267 Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Current or Recent History of Atrial Fibrillation
Primary: Time to First Event of Symptomatic Atrial Fibrillation/Atrial Flutter (AF/AFL) or All Cause Mortality (ACM) During the 24-week Follow-up Period After Establishment of…
Phase 4 N=56 Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
Idiopathic Dilated Cardiomyopathy
Primary: Improvement in Left Ventricular Ejection Fraction (LVEF) at 12 Months — 12; 10; 9 LVEF responders — p=0.685
Phase 2 N=10 Study on the Effect of a Beta Blocker on Increased Sensitivity to Pain in Humans Caused by Opioids
Hyperalgesia
Primary: Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH). — -28…
Phase 4 N=177 A Randomized Controlled Study to Assess the Effects of Bisoprolol and Atenolol on Resting Heart Rate and Sympathetic Nervous System's Activity in Subjects With Essential Hypertension
Hypertension
Primary: Change From Baseline in Baroreflex Sensitivity (BRS) at Attainment of Heart Rate Goal — 7.78; 7.92; 3.27; 2.88 millisecond per millimeter of mercury
Phase 4 N=33 Nebivolol Versus Metoprolol: Comparative Effects on Fatigue and Quality of Life
Hypertension
Primary: Multidimensional Assessment of Fatigue (MAF) Questionnaire: Global Fatigue Score After 4 Weeks of Treatment on Each Drug/Dose Combination. — 18.5; 18.0; 21.0; 20.3 units…
Phase 4 N=22 Comparison of Blood Pressure Medications on Metabolism
Diabetes
Primary: Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline — 0; 0 participants
N/A N=112 Heart Rate Reducing Therapy in Cardiac CT Using Ivabradine and Bisoprolol
Bradycardia
Primary: Heart Rate — 65.1; 62.7 beats per minute
N/A N=39 Antihypertensive Medication Exposure as Risk for Impaired Glucose Tolerance: A PEAR Sub-Study
Prediabetic State
Primary: Number of Participants Diagnosed With Prediabetes or Normal Glucose, by 2 Measurements (Fasting Glucose Measurement and Glucose Measurement After a 2-hour Oral Glucose…
Phase 2 N=23 Propranolol for Sleep Apnea Therapy
Obstructive Sleep Apnea
Primary: Nocturnal Heart Rate (Beats/Min, BPM) — 64.1; 60.2 BPM
N/A N=35 Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
Long QT Syndrome · Cardiac Repolarization
Primary: QTc Response to Exercise on Versus Off Beta-blocker. — 320; 317; 317; 315 ms
Phase 4 N=9 Impact of Beta-blockers on Physical Function in HFpEF
Heart Failure · Heart Failure, Diastolic · Heart Failure With Preserved Ejection Fraction
Primary: Change in Physical Activity When on Beta-blocker Versus When Off Beta-blocker, as Measured by Step Count on Wearable Activity Monitoring Device — 2790.5; 3167.3 Count of…
N/A N=817,337 Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Propranolol/Carvedilol Versus Atenolol/Bisoprolol/Sotalol
Hypertension
Primary: Time to Dementia Onset — 22.96; 19.84; 26.82; 25.84 Incidence rate per 1000 person year
Phase 4 N=186 Comparison of Bisoprolol With Metoprolol Succinate Sustained-release on Heart Rate and Blood Pressure in Hypertensive Patients
Hypertension
Primary: Change From Baseline in Mean Ambulatory Diastolic Blood Pressure (DBP) in the Last 4 Hours After 12-week Treatment — 85.28; 85.68; -4.45; -3.39 mmHg
Phase 2 N=35 Nifedipine (Adalat CR, BAY A1040) High Dose PK/PD Study
Hypertension
Primary: Change of Sitting Blood Pressure — -10.19; -19.88; -10.13; -4.30 mm Hg
Phase 4 N=839 Pharmacogenomic Evaluation of Antihypertensive Responses 2
Hypertension
Primary: Change in Blood Pressure From Baseline to Treatment — -7.56; -7.97; -7.68; -11.70 mmHg — p=<0.0001
Phase 2 N=10 Oral Nadolol for the Treatment of Adults With Mild Asthma
Asthma
Primary: Mean Daily Dose at Study Termination Across Participants — 29.6 mg
Phase 4 N=21 Comparison of Nebivolol and Metoprolol With Exercise and Angiotensin II in Hypertensive Patients
Hypertension
Primary: Forearm Blood Flow — 96; 105 ml/min